体重指数与银屑病关节炎不同进阶治疗中最小疾病活动度达标的关系
基于Gladman Krembil银屑病关节炎项目队列的纵向观察研究,纳入1291例有BMI随访数据的患者,评估BMI与MDA及其组分的关系。结果显示较高BMI独立降低MDA达标 odds(OR 0.97,95%CI 0.94-0.99),该效应在TNFi(除外英夫利西单抗)治疗者中最显著,而在IL-17i、IL-12/23i、IL-23i或JAKi中未见显著影响。
要点
- 较高BMI与银屑病关节炎患者MDA达标率降低独立相关。
- BMI对MDA各组分(除肿胀关节数)均有负向关联。
- TNFi(除外英夫利西单抗)治疗者中高BMI降低MDA达标 odds 最明显。
核心结论
- 高BMI降低银屑病关节炎患者MDA达标 odds,主要影响主观疾病指标。
- 该效应在TNFi(除外英夫利西单抗)治疗患者中最显著。
- 体重管理对优化治疗反应具有重要意义。
研究设计与样本
- 纵向观察性研究,使用Gladman Krembil银屑病关节炎项目队列。
- 纳入随访期间有BMI测量的患者,共1291例,平均年龄44.7岁,56%男性,平均BMI 28.8 kg/m2。
- 采用单变量和多变量广义估计方程及线性混合模型,调整年龄、性别、焦虑/抑郁、纤维肌痛、吸烟、治疗类型和影像学损伤。
- 按六类进阶治疗进行亚组分析:TNFi、IL-17i、IL-12/23i、IL-23i、JAKi和PDE4i。
主要发现
- 较高BMI与MDA达标 odds 降低独立相关(多变量OR 0.97;95%CI 0.94,0.99)。
- 女性、年龄较大、吸烟、纤维肌痛和影像学损伤亦与MDA达标 odds 降低相关。
- BMI与除肿胀关节数外的所有MDA组分呈负向关联。
- 药物启动时较高BMI与TNFi(除外英夫利西单抗)治疗患者MDA达标 odds 降低相关(多变量OR 0.94;95%CI 0.92,0.97)。
- IL-17i、IL-12/23i、IL-23i或JAKi治疗中未见BMI对MDA达标的显著影响;纵向BMI评估同样显示TNFi(除外英夫利西单抗)治疗者MDA达标 odds 降低。
临床怎么用
- 在银屑病关节炎管理中应重视体重管理以优化治疗反应。
- 对于高BMI患者,选择TNFi(除外英夫利西单抗)时需关注MDA达标率可能降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Obesity is a prevalent comorbidity in psoriatic arthritis (PsA). We aimed to evaluate the association between body mass index (BMI) and minimal disease activity (MDA) state in PsA and examine this across different drug classes. METHODS: In a longitudinal observational study using the Gladman Krembil PsA Program cohort, patients with available BMI measurement over follow-up were included. Univariable and multivariable (MV) generalized estimating equations and linear mixed models were used to assess associations between BMI and MDA (and its components) over time, adjusting for age, sex, anxiety/depression, fibromyalgia, smoking, treatment type and radiographic damage. Subgroup analyses evaluated this association across six drug classes: TNF-α inhibitors (TNFi), IL-17 inhibitors (IL-17i), IL-12/23 inhibitors (IL-12/23i), IL-23 inhibitors (IL-23i), Janus kinase inhibitors (JAKi) and phosphodiesterase-4 inhibitors (PDE4i). RESULTS: In 1291 patients (mean age 44.7 years, 56% male, mean BMI 28.8 kg/m2), higher BMI was independently associated with lower odds for MDA (MV, odds ratio [OR] 0.97; 95% CI: 0.94, 0.99) along with female sex, older age, smoking, fibromyalgia and radiographic damage. BMI was negatively associated with all MDA components except swollen joint count. Higher BMI at drug initiation was associated with reduced odds for MDA state in TNFi-treated patients excluding infliximab (MV, OR 0.94; 95% CI: 0.92, 0.97), while no significant effect was seen for IL-17i, IL-12/23i, IL-23i or JAKi. Longitudinal BMI assessment similarly showed reduced MDA odds with TNFi (excluding infliximab). CONCLUSIONS: High BMI decreases the odds for MDA in PsA, mainly affecting subjective disease measures. This effect is most pronounced in patients treated with TNFi (except infliximab). This underscores the importance of weight management in optimizing treatment response.
引用
- Mehta P, Yang M, Kharouf F, et al. Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy. Rheumatology (Oxford). 2026. PMID: 42281273. doi:10.1093/rheumatology/keag303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。